PATENT CLAIM ANALYSIS

Application Number: 16196955
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-08
Patent Classification: ["514", "300000"]

Abstract:
The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

Claim (Index 35):
The method of  claim 34 , wherein the primary response genes comprise one or more of IL-1\u03b2, IL-10, inducible nitric oxide synthase (iNOS), IL-6, TNF\u03b1, MMP-1, MMP-3, MMP-9, IL-1a, NFKB1, SOD2, CTSS, MMP-13, ADAMTS4 (aggrecanase), CDKN1A, F3, IL-15, ADM, FAS, CD83, EGFR, CFB, IL1RN, CXCL1, BCL2A1, IL-2, BIRC3, PTGS2, ICAM1, NFKB1A, NR4A2, RELA, CSF1, IL-8, TNFRSF1B, CCL5, RELB, VCAM1, REL, CCL2, CD40, CXCL9, CSF2, CXCL2, CSF3, and CXCL10.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 98.0
- Lexical Diversity: 1.70455
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15356231', '14351878', '15517476', '10740098', '14481841']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8328297835565526
- 35 USC 102 Novelty (BERT): 0.6674903827933264
- Combined Prediction Score: 0.81629584348023
- Mean Citation Score: 539.058552
- Max Citation Score: 740.2954
- Similarity Product: 600.5137017688037

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test